Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliv ...

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company's Genio® device is complete, U.S. approval on track for the end of 2024 U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised Nyxoah – NASDAQ Closing Bell Ceremony 29 août 2024 Mont-Saint-Guibert, Belgium – September 2, 2024 10:05pm CET / 4:05PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (" ...

Nyxoah S.A. (NASDAQ:NYXH) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and Investor Relations Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Suraj Kalia - Oppenheimer Edward White - H.C. Wainwright Joseph Federico - Stifel Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day, everyone, and thank you for standing by. Welcome to Nyxoah Second Quarter 2024 Earnings Conference Call. [O ...

Nyxoah SA (NYXH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.22%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.45, delivering no surprise. Over the last four quarters, the company has surpassed consensus E ...

Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial resu ...

Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by strong operational execution. Scott is a passionate advocate for people and talent development. Scott graduated with the Superintendent's Award for Excellence (Star Wreath) from the United States Military Academy at West Point, NY. After serving as a Captain in the U.S. Army, Scott received his MBA from the University of Min ...

Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U. ...

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the ...

Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration (FDA). About Nyxoah For more information, please visit http://www.nyxoah.com/. should not be taken as a re ...

100 "2018 ESOP Warrants" issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares); 400,500 "2020 ESOP Warrants" issued on February 21, 2020, entitling their holders to subscribe to a total number of 400,500 securities carrying voting rights (all ordinary shares); and 1,057,625 "2021 ESOP Warrants" issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,057,625 securities carrying vot ...